
Current and Future Role of PARP Inhibitors in Metastatic Triple-Negative Breast Cancer



Melinda Telli, M.D.

Director, Breast Cancer Program Stanford Cancer Institute Associate Professor of Medicine Stanford University School of Medicine


PARP Inhibitors



- Veliparib Phase III data
- Niraparib
- Olaparib Approved 1/12/2018
- Rucaparib
- Talazoparib Approved 10/16/2018
- NCCN guidelines endorse germline BRCA1/2 mutation testing for all metastatic breast cancer patients

Murai J, Pommier Y. Classification of PARP Inhibitors Based on PARP Trapping and Catalytic Inhibition, and Rationale for Combinations with Topoisomerase I Inhibitors and Alkylating Agents. In: Curtin NJ, Sharma RA, eds. *PARP Inhibitors for Cancer Therapy*. New York: Springer International Publishing;2015:261-274.

PARP inhibitors active in BRCA1/2 mutated cancers



NCCN NCCN NCCN Network®

RECURRENT/STAGE IV (M1) DISEASE

CLINICAL	WORKUP ^a	
STAGE Stage IV (M1)	 History and physical exam Discuss goals of therapy, adopt shared decision-making, and document course of care CBC Comprehensive metabolic panel, including liver function tests and alkaline phosphatase Imaging for systemic staging: Chest diagnostic CT with contrast Abdominal ± pelvic diagnostic CT with contrast or MRI with contrast Brain MRI with contrast if suspicious CNS symptoms Spine MRI with contrast if back pain or symptoms of cord compression Bone scan or sodium fluoride PET/CT^{SS} (category 2B) 	See Treatment of Local and Regional Recurrence (BINV-19) and Supportive care ^{eee}
Recurrent	> X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan	\backslash
Initial biomarkers at recurrent/metastatic presentation	 Biomarker testing: Biopsy of first recurrence of disease Evaluation of ER/PR and HER2 status to differentiate recurrent disease from new primary^{d,ccc,ddd} Comprehensive germline and somatic profiling to identify candidates for additional targeted therapies, see Additional Targeted Therapies and Associated Biomarker Testing for Recurrent or Stage IV (M1) Disease (BINV-R) Genetic counseling if patient is at risk^e for hereditary breast cancer Assess for distress^g 	See Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-20) ^{fff} and Supportive care ^{eee}
^a For tools to aid opt	imal assessment and management of older adults,	

For tools to aid optimal assessment and management of older adults see NCCN Guidelines for Older Adult Oncology.

d <u>See Principles of Biomarker Testing (BINV-A)</u>.

^e For risk criteria, <u>see NCCN Guidelines for Genetic/Familial High-Risk</u> <u>Assessment: Breast, Ovarian, and Pancreatic</u>.

g See NCCN Guidelines for Distress Management.

- ^{ss} Bone scan or sodium fluoride PET/CT may not be needed if FDG PET/CT is performed and clearly indicates bone metastasis, on both the PET and CT component.
- ^{tt} FDG PET/CT can be performed at the same time as diagnostic CT. FDG PET/CT is most helpful in situations where standard staging studies are equivocal or suspicious. FDG PET/CT may also be helpful in identifying unsuspected regional nodal disease and/or distant metastases when used in addition to standard staging studies.

^{ccc} False-negative ER and/or PR determinations occur, and there may be discordance between the ER and/or PR determination between the primary and metastatic tumor(s). Therefore, endocrine therapy with its low attendant toxicity may be considered in patients with non-visceral or asymptomatic visceral tumors, especially in patients with clinical characteristics predicting for a HR-positive tumor (eg, long disease-free interval, limited sites of recurrence, indolent disease, older age).

^{ddd} In clinical situations where a biopsy cannot safely be obtained but the clinical evidence is strongly supportive of recurrence, treatment may commence based on the ER/PR/HER2 status of the primary tumor.


eee See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care.

fff For the treatment of brain metastases, see <u>NCCN Guidelines for Central Nervous</u> <u>System Cancers</u>.

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Phase III OlympiAD Trial Olaparib in gBRCA1/2 Mutant Advanced Breast Cancer



Primary endpoint: PFS (blinded central review) Secondary endpoints: Safety, OS, ORR, and health-related QOL scores

Phase III OlympiAD Trial PFS with Olaparib Monotherapy




Months since Randomization

- **Objective Response Rate**
- 59.9% Olaparib
- 28.8% Chemotherapy

Robson M, et al. NEJM, 2017


Phase III OlympiAD Trial Final OS with Olaparib Monotherapy



Robson, M et al. Ann Oncol, 2019


Phase III EMBRACA Trial

Talazoparib in gBRCA1/2 Mutant Advanced Breast Cancer




Secondary Endpoints: OS, ORR, CBR24, Safety

Phase III EMBRACA Trial PFS with Talazoparib Monotherapy




Litton JK, et al. NEJM, 2018

Phase III EMBRACA Trial Final OS with Talazoparib Monotherapy




Litton JK, et al. Annals Oncol, 2020

Phase III BROCADE 3 Trial Carboplatin + Paclitaxel +/- Veliparib




Primary Endpoint: PFS by Investigator Assessment



Dieras V, et al. Lancet Oncol, 2020


Secondary Endpoint: Overall Survival (Interim Analysis)



elected open-label veliparib as 1st subsequent therapy

Dieras V, et al. Lancet Oncol, 2020

Talazoparib Beyond BRCA (TBB)



Cohort B mutations:

PALB2	RAD51C
CHEK2	RAD51D
ATM	FANCA
NBN	FANCC
BARD1	FANCD2
BRIP1	FANCE
PTEN	FANCF
MRE11	FANCG
ATR	FANCL
RAD50	






#ASCO19 Slides are the property of the author, permission required for reuse.

PRESENTED BY: Joshua Gruber, MD, PhD

Talazoparib Beyond BRCA cohort B

Best Overall Responses

All Patients




Gruber JJ, et al. ASCO 2019



#ASCO19 Slides are the property of the author, permission required for reuse.

PRESENTED BY: Joshua Gruber, MD, PhD

TBCRC-048: Olaparib Expanded




Eligible mutations:


<u>Germline or Somatic</u>					
PALB2	RAD51C				
CHEK2	RAD51D				
ATM	FANCA				
NBN	FANCC				
BARD1	FANCD2				
BRIP1	FANCE				
MRE11A	FANCF				
ATR	FANCM				
RAD50					
<u>Somatic</u> BRCA1					

BRCA2

Best Overall Responses: Cohort 1 (Germline)



Best Overall Responses: Cohort 2 (Somatic)




PRESENTED AT:

ANNUAL MEETING

TOPACIO: Niraparib + Pembrolizumab in mTNBC

Preclinical studies demonstrated synergistic activity of PARPi + anti-PD-1, regardless of *BRCA* mutational status or PD-1 sensitivity

- Potential Mechanism of Action
 - Unrepaired DNA damage resulting from niraparib treatment leads to the abnormal presence of DNA in the cytoplasm, activating <u>St</u>imulator of <u>Interferon Genes</u> (STING) pathway
 - Activation of the STING pathway leads to increased expression and release of type 1 interferons, subsequent induction of γinterferon, and intratumoral infiltration of effector T-cells



1. Huang J et al. Biochem Biophys Res Commun. 2015 Aug 7;463(4):551-6; 2. Jiao SP et al. Clin Cancer Res. 2017 Jul 15;23(14):3711-3720; 3. Sato H et al. Nat Commun. 2017 Nov 24;8(1):1751



PRESENTED BY: Shaveta Vinayak, MD, MS

JAMA Oncology | Original Investigation

Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

Shaveta Vinayak, MD, MS; Sara M. Tolaney, MD, MPH; Lee Schwartzberg, MD; Monica Mita, MD; Georgia McCann, MD; Antoinette R. Tan, MD; Andrea E. Wahner-Hendrickson, MD; Andres Forero, MD; Carey Anders, MD; Gerburg M. Wulf, MD, PhD; Patrick Dillon, MD; Filipa Lynce, MD; Corrine Zarwan, MD; John K. Erban, MD; Yinghui Zhou, PhD; Nathan Buerstatte, BS, MPH; Julie R. Graham, PhD; Sujata Arora, MS; Bruce J. Dezube, MD; Melinda L. Telli, MD


- 47 evaluable patients with mTNBC
- 1st-3rd line
- Included patients with platinum resistant disease


• ORR = 21%



```
Vinayak S, et al. JAMA Oncology 2019
```

Figure 2. Antitumor Activity of Niraparib in Combination With Pembrolizumab by Biomarker Status





Select PARP inhibitor & PD-1/PD-L1 Inhibitor Trials

Trial	Phase	Treatment Arms	Inclusion	Primary Outcomes
DORA NCT03167619	II	• Olaparib • Olaparib/durvalumab	 TNBC 1st / 2nd line with CR/PR/SD after 4 cycles of platinum induction therapy 	PFS
MEDIOLA NCT02734004	1/11	• Olaparib/durvalumab	•HER2- <i>, gBRCA+</i> 1 st / 2 nd line •HER2- <i>,</i> mHRR+ 1 st / 2 nd line	ORR/DCR
TOPACIO/ KEYNOTE-162 NCT02657889	II	• Niraparib/pembrolizumab	• TNBC, 1 st – 3 rd line	ORR
JAVELIN PARP MEDLEY NCT03330405	II	• Talazoparib/avelumab	•TNBC, 1 st – 3 rd line •HR+, DDR+, 1 st – 3 rd line	ORR
KEYLYNK-009 NCT04191135	/	 Olaparib/pembrolizumab GC/pembrolizumab 	 TNBC 1st line with CR/PR/SD after 4-6 cycles of gem/carbo + pembrolizumab 	PFS/OS

